Nguyen, Tuan M. http://orcid.org/0000-0003-4879-3962
Sreekanth, Vedagopuram
Deb, Arghya
Kokkonda, Praveen
Tiwari, Praveen K.
Donovan, Katherine A. http://orcid.org/0000-0002-8539-5106
Shoba, Veronika
Chaudhary, Santosh K. http://orcid.org/0000-0001-9979-9323
Mercer, Jaron A. M. http://orcid.org/0000-0001-7078-614X
Lai, Sophia
Sadagopan, Ananthan http://orcid.org/0000-0001-6306-4907
Jan, Max
Fischer, Eric S.
Liu, David R. http://orcid.org/0000-0002-9943-7557
Ebert, Benjamin L. http://orcid.org/0000-0003-0197-5451
Choudhary, Amit http://orcid.org/0000-0002-8437-0150
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Institute of General Medical Sciences (R01 GM137606, R01 GM132825, R35 GM118062)
United States Department of Defense | Defense Advanced Research Projects Agency (N66001-17-2-4055)
U.S. Department of Health & Human Services | NIH | National Cancer Institute (CA214608, CA218278)
U.S. Department of Health & Human Services | NIH | National Institute of Biomedical Imaging and Bioengineering (R01 EB031172, R01 EB027793)
Article History
Received: 23 December 2021
Accepted: 13 October 2023
First Online: 18 December 2023
Competing interests
: Broad Institute has filed a patent application including the work described herein. A.C. is a founder and Scientific Advisory Board (SAB) member in Photys therapeutics. E.S.F. is a founder, SAB member, and equity holder in Civetta, Lighthorse, Proximity and Neomorph (board of directors), SAB member and equity holder in Photys and Avilar, and a consultant to Astellas, Novartis, Sanofi, Deerfield and EcoR1. The Fischer lab receives or has received research funding from Novartis, Astellas, Interline and Deerfield. D.R.L. is a consultant and co-founder of Exo Therapeutics, a company that develops small-molecule therapeutics. K.A.D. is a consultant to Kronos Bio and Neomorph Inc. The remaining authors declare no competing financial interests.